导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 26.34% | 123/4724 |
| 近一周 | -2.27% | 1608/5400 |
| 近一月 | -10.14% | 4918/5359 |
| 近一季 | -11.99% | 3739/5149 |
| 近半年 | 21.14% | 123/4864 |
| 近一年 | 33.37% | 152/4324 |
| 近两年 | 174.95% | 108/2940 |
| 近三年 | 113.52% | 91/2242 |
| 成立以来 | 130.06% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.75% 3685/4961 |
99.84% 103/5312 |
- - |
- - |
| 2025 | 42.00% 712/4813 |
3.35% 1106/3635 |
-0.23% 2858/4076 |
48.11% 395/4524 |
-7.02% 3756/4813 |
| 2024 | 23.45% 335/3463 |
-10.70% 2370/2808 |
0.78% 544/3014 |
16.94% 1304/3129 |
17.31% 91/3463 |
| 2023 | -2.44% 581/2656 |
17.09% 177/2280 |
-6.96% 1750/2385 |
-9.18% 1785/2515 |
-1.40% 320/2655 |
| 2022 | -36.16% 1738/2207 |
-21.84% 1658/1919 |
-0.10% 1593/2016 |
-18.38% 1702/2113 |
0.17% 1531/2208 |
| 2021 | 26.83% 94/1822 |
-9.01% 1099/1255 |
37.87% 22/1330 |
-4.25% 694/1466 |
5.60% 283/1822 |
| 2020 | 50.40% 167/1250 |
9.47% 21/1028 |
29.45% 74/1067 |
-0.83% 1059/1164 |
7.01% 732/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 国泰CES半导体芯片行业ETF联接A VS. 长安沪深300非周期A(740101) |